Reuters logo
AstraZeneca's asthma drug fails in study
May 10, 2017 / 6:40 AM / in 5 months

AstraZeneca's asthma drug fails in study

May 10 (Reuters) - Drugmaker AstraZeneca Plc said its asthma drug failed to meet the main goal of significantly reducing the annual asthma exacerbation rate in a late-stage study.

The drug, tralokinumab, failed against placebo, the company said, adding that it would now await the results from a second round of late-stage trial of the drug in the second half of the year.

Asthma affects about 315 million people worldwide, with about 10 percent suffering from severe asthma, the company said. (Reporting by Sanjeeban Sarkar in Bengaluru; Editing by Amrutha Gayathri)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below